San Diego – March 7, 2016 – GenomeDx Biosciences today announced that three abstracts featuring Decipher GRID (Genomics Resource Information Database) and Decipher Prostate Cancer Classifier tests will be presented at the 31st Annual EAU Congress (EAU16) held March 11-15 in Munich, Germany. The Annual EAU Congress is Europe’s largest urological event showcasing the latest and most comprehensive research in the urological field.
The abstract, titled “Utilization of a genomic classifier for the prediction of metastasis following postoperative salvage radiation therapy,” was chosen as one of the best posters at EAU16, and will be displayed at the e-Posters area (Foyer ICM- level 0) as of Friday March 11, as well as during poster session 58.
Presentations
Sunday, March 13
Title: Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk
Thematic Session: 03 (10:30 a.m. to noon CET)
Poster Session: 35 (12:15 p.m. to 1:45 p.m. CET)
Poster Number: 435
Monday, March 14
Title: Utilization of a genomic classifier for the prediction of metastasis following postoperative salvage radiation therapy
Poster Session: 58 (8:45 a.m. to 10:15 a.m. CET)
Poster Number: 729
Title: Decipher genomic classifier measured on prostate biopsy predicts 10 year metastasis risk
Poster Session: 58 (8:45 a.m. to 10:15 a.m.)
Poster Number: 730
About Decipher® Prostate Cancer Classifier Tests
Our Decipher prostate cancer classifier tests are currently comprised of Decipher Biopsy and Decipher Post-Op. These commercially available genomic tests provide an assessment of tumor aggressiveness based on the patient’s unique genomic profile. Decipher Biopsy is indicated for men after biopsy diagnosis and Decipher Post-Op is indicated for men after prostate removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups to better determine which patients will likely benefit from additional treatment and which will not, thereby enabling improved decision-making and helping low-risk patients avoid unnecessary treatments that have serious adverse side effects and result in unnecessary costs to the healthcare system. Studies of thousands of patients from leading cancer centers, published in multiple peer-reviewed journals, demonstrate that the Decipher tests can more accurately predict disease aggressiveness than traditional clinical measures, such as PSA and Gleason score. Decipher Post-Op is covered by Medicare and by a number of private payors and preferred provider organizations representing, together with Medicare, about 70% of the approximately 66 million adult men in the United States age 40 or older who are at increased risk of being diagnosed with prostate cancer.
Learn more at www.DecipherTest.com
About Decipher GRID™
Our Decipher Genomics Resource Information Database (Decipher GRID) is a genomic data sharing platform that provides a foundation for open and interactive research collaboration and knowledge creation. Decipher GRID is a rapidly growing database that contains genomic profiles of thousands of patients, and constitutes what we believe to be the world’s largest shared, clinically-annotated genomic expression database in urologic oncology and one of the world’s largest global RNA expression databases utilizing cloud-based analytics. We believe Decipher GRID gives rise to new opportunities for information technology-enabled genomic solutions and enables more rapid discovery, development, commercialization and adoption of existing and new products. Through Decipher GRID, GenomeDx is building a suite of genomic tests to assist physicians and patients with clinical decision-making from disease screening through late-stage therapy.
Learn more at www.DecipherGRID.com
About GenomeDx Biosciences
GenomeDx Biosciences uses the power of collaborative genomics to transform the management and treatment of cancer patients. GenomeDx has built Decipher GRID, a large genomics database in urologic oncology that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that provide more accurate and useful diagnostic information than both traditional diagnostic tools and existing genomic tests. GenomeDx’s Decipher Post-Op and Decipher Biopsy are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient’s unique genomic profile. GenomeDx is based in San Diego, California and Vancouver, British Columbia.
Learn more at www.GenomeDx.com
Media Contact:
Ian Stone
Canale Communications
619-849-5388
ian@canalecomm.com